Neutrophil-lymphocyte and Platelet-lymphocyte Ratios and Their Relations to Vascular Comlications and Glycemic Control in Patients With Type 2 Diabetes Attending The Diabetes Center of Assiut University Hospitals

October 3, 2023 updated by: Ammar Ashraf fathy, Assiut University
Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Vascular complications of DM result from various disorders including metabolic, cellular, and blood disturbances. Excessive production of pro-inflammatory adipokines from adipose tissue, resulting in low-grade chronic inflammation, causing insulin resistance (IR) and type 2 DM [3]. Hematological changes affecting the red blood cells (RBCs), white blood cells (WBCs), platelet function, and the coagulation factors are detected to be associated with DM . It is important to add that, high WBC count, one of the chief components of inflammatory process, sharing to atheroscle-rosis development and cardiovascular diseases (CVD) . Lately, the neutrophil-to-lymphocyte (N/L) and the platelet-to-lymphocyte (P/L) ratios, were offered as markers of inflammation in cardiac diseases, neoplasms and diabetes-related complications . Moreover, high leucocyte counts have been used as diagnostic and prognostic markers in vascular complication of diabetes

Study Type

Observational

Enrollment (Estimated)

106

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

Description

Inclusion Criteria:

  • Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C <7and ages ranging from ≥18 old. And poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old

Exclusion Criteria:

  • Patients with, type 1 diabetes mellitus

    1. Idiopathic thrombocytopenic purpura,
    2. liver cell failure
    3. Myeloproliferative neoplasm
    4. patients on anticoagulant drugs , anti platelet drugs or on steroids were excluded from the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C <7and ages ranging from ≥18 old.
Radiation: Echocardiogram
Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
Other Names:
  • ECG
  • Echo
  • ALB / cr ratio
  • Fundus examination
  • Doppler on lower limbs
  • Nerve conduction
2
Type 2 diabetes mellitus (T2DM) patients with poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old
Radiation: Echocardiogram
Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
Other Names:
  • ECG
  • Echo
  • ALB / cr ratio
  • Fundus examination
  • Doppler on lower limbs
  • Nerve conduction

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neutrophil-to-lymphocyte ratio and platelets to lymphocytes ratio
Time Frame: Basline
Measurement of Neutrophils to lymhocyte ratio and platelets to lymhocyte ratio in patients with type 2 DM
Basline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HbA1c with good glycemic control and have HBA1C lower than 7and poor glycemic control and have HBA1C higher than 7with prescence or abscence of vascular complications
Time Frame: Basline
Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
Basline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2023

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

October 3, 2023

First Submitted That Met QC Criteria

October 3, 2023

First Posted (Estimated)

October 9, 2023

Study Record Updates

Last Update Posted (Estimated)

October 9, 2023

Last Update Submitted That Met QC Criteria

October 3, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NLR and PLR and in type 2 DM

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vascular Complication, Diabetic

Clinical Trials on Echocardiogram

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe